Effects of recombinant human brain natriuretic peptide on renal function in patients with acute myocardiol infarction and heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005796

Enrollment

Unknown

Registered

2014-11-24

Start date

2015-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardiol infarction and heart failure

Interventions

rhBNP Group:intravenous infusion of rhBNP

Control:intravenous infusion of nitroglycerin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. AMI within 7 days from symptom onset; 2. first AMI; 3. KillIP classification II to III, or level of BNP more than 500pg/ml; 4. with or without reperfusion therapies (thrombolysis or primary PCI).

Exclusion criteria

Exclusion criteria: 1. cardiac shock; 2. combined with Heart valve disease, hypertrophic cardiomyopathy, or idiopathic cardiomyopathy, etc; 3. underwent CABG therapy; 4. contraindications of Antiplatelet and anticoagulant drugs; 5. mechanical ventilation; 6. Serious liver and kidney dysfunction; 7. Refused to participate.

Design outcomes

Primary

Measure	Time frame
renal function;heart function;major adverse cardiac events;	—

Countries

China

Contacts

Public ContactWang Yanbo

doctorwangyanbo@126.com+86 13931858363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026